Becton, Dickinson and Company
One Becton Drive
666 articles with Becton, Dickinson and Company
The Board of Directors of BD has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter.
BD, a leading global medical technology company, announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys™ Informatics.
BD Acquires the Medical Business Assets of CUBEX LLC, Broadening Automated Dispensing Portfolio Across Care Continuum
BD, a leading global medical technology company, announced it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held company that develops cloud-based software offerings for advanced medication management.
BD Announces Canadian Government Order of More Than 7 Million Portable, Rapid Point-of-Care Antigen Tests to Detect SARS-CoV-2 in 15 minutes
BD, a leading global medical technology company, announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been authorized for use by Health Canada under Interim Order.
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel 2020 Virtual Healthcare Conference November 16, 2020 9:20 a.m. EDT Jefferies Virtual London Healthcare Conference November
BD, a leading global medical technology company, reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30, 2020.
BD Receives Order from Dutch Ministry of Health for More than Nine Million 15-minute COVID-19 Antigen Tests
The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor™ Plus System to be delivered in The Netherlands by mid-November
BD, a leading global medical technology company, announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of Dave Hickey to executive vice president and president, Life Sciences segment, both effective January 1, 2021.
CerTest Biotec and BD Announce CE Mark for Combination COVID-19, Influenza, RSV Test on BD MAX™ Molecular Diagnostic System
CerTest Biotec, along with BD, a leading global medical technology company, announced that the VIASURE SARS-CoV-2 Real Time PCR Detection Kit adapted for the BD MAX™ System has been CE marked* to the IVD Directive.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
BD marks 25 years with Mercy Ships: Donates $1M to support launch of world's largest NGO hospital ship
Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare access
BD Granted FDA 510(k) Clearance for BD FACSLyric™ Flow Cytometer with Newly Integrated BD FACSDuet™ Sample Preparation System
BD FACSDuet™ Sample Preparation System, now available in the U.S., as the first fully automated sample-to-answer solution when integrated with the BD FACSLyric™ Flow Cytometer
BD announced that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday, November 5, 2020, at 8:00 a.m. BD will issue a press release detailing the quarter's earnings earlier that morning..
BD Announces CE Mark of Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes
BD, a leading global medical technology company, announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the IVD Directive.
BD Submits Pre-Market Approval Supplement to FDA to Enable ThinPrep® Pap Test™ PreservCyt® Solution to be Used with the BD Onclarity™ HPV Assay
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep ® Pap Test™ PreservCyt ® Solution vial as an approved sample type for its B
BD Announces FDA Classifications for August 4th Recalls of BD Alaris™ System Hardware for Keypads, Incorrect Module Types and/or Sizes, and Channel Error
BD, a leading global medical technology company, provided an update on previously announced voluntary recalls of the BD Alaris™ System.
New Head-to-Head Study Demonstrates Equivalency and Accuracy of COVID-19 Rapid Point-of-Care Tests, Despite Different Test Sensitivity Claims
Results show clinical study design may influence performance estimates and published sensitivity claims of SARS-CoV-2 antigen tests
BD, a leading global medical technology company, announced that it will present at the following upcoming virtual investor healthcare conferences
BD and BD Foundation commit $7.8 million to helping community health centers expand innovative care to patients
BD together with the BD Foundation, its charitable affiliate, committed $7.8 million in monetary grants and product donations over the next three years to support the continued expansion of the BD Helping Build Healthy Communities™ initiative – a unique public-private partnership launched in 2013 and implemented jointly by Direct Relief and the National Association of Community Health Centers.
BD, a leading global medical technology company, reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020.